← All trials
NCT07284901
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2025
- Primary completion
- Mar 27, 2028
- Completion date
- Apr 24, 2028
- First posted
- Dec 16, 2025
- Last posted
- Dec 18, 2025
- Enrollment
- 1700
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- KaileraLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.